▲ Peaking
Business
🔮 fades
Bristol Myers' blood cancer cell therapy succeeds in mid-stage trial
Bristol Myers Squibb shares rise following successful Phase 2 trial results for its blood cancer cell therapy, Arlocabtagene Autoleucel.